This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Developing Opportunities for the Dermatology, Ophthalmology, Urology, and Hospital Infection Markets
Data Expected From Multiple Phase 2 Clinical Trials in 2011
EMERYVILLE, Calif., Feb. 2, 2011 (GLOBE NEWSWIRE)
-- NovaBay Pharmaceuticals, Inc. (NYSE Amex:NBY), a clinical stage biotechnology company developing its first-in-class, anti-infective Aganocide
® compounds for the topical treatment and prevention of antibiotic-resistant infections, provided a synopsis of its accomplishments and progress during 2010, as well as the company's outlook for 2011.
NovaBay is developing commercial opportunities for its Aganocide portfolio of anti-infectives in four distinct healthcare markets: dermatology, ophthalmology, urology and hospital infections. Each of these market segments contain indications that are poorly served or have no approved FDA treatments available, with multiple hundred-million to billion-dollar revenue potential. NovaBay's strategy is to address these market opportunities either through partnerships and collaborations or by building an internal organization to strategically market its own products when appropriate from a commercial standpoint.
In July 2010 NovaBay announced positive results in a 129-patient, Phase 2a impetigo skin infection study. The results showed 92% of the patients in NovaBay's highest dose were cured of the highly contagious infection following seven days of treatment with NovaBay's lead Aganocide (NVC-422) topical gel. Furthermore, methicillin-resistant
Staphylococcus aureus (MRSA) is becoming an escalating problem, as an ever-increasing portion of patients are infected with this "superbug" in impetigo. Patients in the study infected with MRSA impetigo infection, were successfully treated. As resistance to antibiotics becomes a critical public health issue, NovaBay intends to aggressively pursue the development of non-antibiotic anti-infectives that are unlikely to cause resistance, as a first-line treatment for a range of topical infections.
Based on the Phase 2a clinical trial results, in December 2010, NovaBay and Galderma S.A., the world's leading dermatology company, agreed to expand their partnership to focus on the development of NovaBay's Aganocide compound NVC-422 for the topical treatment of impetigo as well as developing its technology for acne. This expansion will provide NovaBay with the additional funding and resources required for the clinical development of its NVC-422 topical gel formulation for impetigo. Moving NVC-422 gel into Phase 2b clinical development in 2011 is the current top priority, with the potential to move into Phase 3 development during 2012. Galderma will fund all development activities relating to Impetigo and acne.